Stock DNA
Pharmaceuticals & Biotechnology
SEK 15 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.43
-121.11%
1.36
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Mar 2025)
Net Profit:
-4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-60.0%
0%
-60.0%
6 Months
-74.55%
0%
-74.55%
1 Year
-89.81%
0%
-89.81%
2 Years
-90.79%
0%
-90.79%
3 Years
-98.64%
0%
-98.64%
4 Years
-98.97%
0%
-98.97%
5 Years
-97.93%
0%
-97.93%
PolarCool AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.51%
EBIT Growth (5y)
-17.16%
EBIT to Interest (avg)
-10.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.66
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.11
EV to EBIT
-1.39
EV to EBITDA
-1.65
EV to Capital Employed
2.97
EV to Sales
7.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-213.49%
ROE (Latest)
-121.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
0.50
0.60
-16.67%
Operating Profit (PBDIT) excl Other Income
-3.20
-2.40
-33.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.80
-2.90
-31.03%
Operating Profit Margin (Excl OI)
-7,230.80%
-5,080.30%
-215.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -16.67% vs 0.00% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -31.03% vs 0.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2.10
1.40
50.00%
Operating Profit (PBDIT) excl Other Income
-9.10
-11.10
18.02%
Interest
0.70
0.30
133.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.00
-12.10
9.09%
Operating Profit Margin (Excl OI)
-4,959.30%
-9,011.10%
405.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 50.00% vs -26.32% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 9.09% vs 0.82% in Dec 2023
About PolarCool AB 
PolarCool AB
Pharmaceuticals & Biotechnology
Polarcool AB is a Sweden-based medical device company specializing in sports medicine. The Company focuses on of concussive and sub-concussive brain injuries. It develops a portable brain cooling device called PolarCap System. The PolarCap System consists of a cooling unit and a silicone-based cooling cap alongside neoprene insulation, cooling the head and neck via a circulating coolant during a procedure that takes approximately 45-60 minutes. The idea behind it is the reduction of brain temperature of individuals suffering from a concussion or participating in an activity where repetitive head impact occurs, such as contact and combat sports, in order to prevent or limit long term cognitive impairment. The device undergoes preclinical cohort study for concussion among hockey players and a preclinical study for indication of sub-concussive repetitive head impact among American football players.
Company Coordinates 
Company Details
Medicon Village, Scheelevagen 2 , Lund None : 223 81
Registrar Details






